FDA approves ViiV Healthcare’s Dovato for adolescent HIV treatment
The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Dovato (dolutegravir/lamivudine) to treat HIV-1 infection in adolescents.
The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Dovato (dolutegravir/lamivudine) to treat HIV-1 infection in adolescents.
Bavarian Nordic has announced the commercial availability of JYNNEOS, which is claimed to be the only FDA-approved vaccine for mpox, in the US.
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences’ supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets to treat chronic hepatitis B virus (HBV) in paediatric patients.
Baseimmune, a biotech firm specialising in artificial intelligence (AI)-driven vaccine development, has announced the successful closure of a £9m Series A funding round.
Exicure and Bluejay Therapeutics have reached a patent licencing agreement for the development of cavrotolimod as a potential hepatitis treatment.
Novartis has acquired US-based clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5bn upfront.
The US Food and Drug Administration (FDA) has granted clearance to Gilead Sciences’ supplemental new drug application (sNDA) of Veklury (remdesivir) for use in Covid-19 patients.
Medicines Patent Pool (MPP), a UN-supported international public health organisation, has signed seven sublicence agreements for Japanese pharmaceutical firm Shionogi & Co's Ensitrelvir fumaric acid.
Innoviva Specialty Therapeutics has received approval from the US Food and Drug Administration (FDA) for XACDURO to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
The US Food and Drug Administration (FDA) has finished a filing review of Valneva’s Biologics License Application (BLA) for single-shot chikungunya vaccine candidate VLA1553.